News | April 28, 2023
Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Bridging the gap between histopathology and molecular pathology
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
Malaria is a life-threatening parasitic infection that is spread by the bites of mosquitoes carrying the Plasmodium parasite
Apollo continues to invest in genomics technology and research for better patient care
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
